Applying the Data and Practical Recommendations for Tailoring Treatment Selections for AML

Program

Treating Newly Diagnosed AML

Case #1: John

Case #1: Marrow Results

Case #1: Marrow Results (cont)

Workup for AML in 2019

Diagnostic Workup for AML in 2019

Polling Question

Phase 3: 7+3 Plus Midostaurin vs Placebo -- CALGB 10603 (RATIFY)

Phase 3: 7+3 Plus GO vs 7+3 -- ALFA-0701 Study

Phase 3: 7+3 Plus GO vs 7+3 -- ALFA-0701 Study

Meta-Analysis of Gemtuzumab Plus 7+3

Panel Discussion

Case #2: Nancy

Case #2: Nancy (cont)

Case #2: Nancy (cont)

Polling Question

Phase 3: GO vs BSC in Older Treatment-Naive AML -- EORTC/GIMEMA AML 19

Glasdegib + LDAC Improves Overall Survival

Venetoclax + Hypomethylating Agents --- Phase 1b

Upfront Therapy of IDH Mutant AML

Panel Discussion

Case #3: Mary

Marrow Results for Mary

Polling Question

Outcomes of 7+3 in Secondary AML

Liposomal Cytarabine/Daunorubicin (CPX-351) vs 7+3 in Older, Newly Diagnosed, High-Risk AML Patients

Liposomal Cytarabine/Daunorubicin (CPX-351) vs 7+3 in Older, Newly-Diagnosed, High-Risk AML Patients

CPX-351 vs 7+3 in Older, Newly-Diagnosed, High-Risk AML: Landmark Analysis After Transplant

Venetoclax + Azacitidine/Decitabine -- Phase 1b

Panel Discussion

Question & Answer Session

Treating Relapsed/Refractory AML

Case #4: Joseph

Case #4 (cont)

Polling Question

Treatment of R/R FLT3–Mutated AML

Single-Agent FLT3 Inhibitor for Relapsed AML

Panel Discussion

Treatment of R/R IDH–Mutated AML

Case #5: Susan

Polling Question

Panel Discussion

What Is Ahead for AML?

Conclusions

Take-Home Messages

Audience Q&A

Abbreviations

Abbreviations (cont)